


California Pacific
Medical Center
Research Institute

*Transforming cancer
research to deliver
fully personalized
cancer care*



Leading-edge cancer research and clinical trials at Sutter Health's California Pacific Medical Center Research Institute

Thousands of cancer patients choose Sutter Health's CPMC annually for superior diagnosis, treatment and follow-up care, informed by the latest innovative research.

With decades of cancer research experience at California Pacific Medical Center Research Institute (CPMCRI), top national rankings and renowned leadership in cancer treatment and clinical trials, CPMC pioneers medical advances that improve outcomes and provide a better chance of cure.

New and innovative therapies are available at CPMC years before becoming standard-of-care, with over fifty phase 1 to pivotal phase 3 cancer clinical trials consistently offered to our patients.

Few cancer centers worldwide have evolved to help lead a new paradigm of precision medicine for fully individualized treatment. CPMCRI's Cancer Avatar Project—a living biology approach to translational research—will help realize that goal through our unique focus on improving cancer clinical care.



Christie Stokes, an ovarian cancer survivor treated at CPMC, and husband Nick

“At CPMC, we are committed to building upon our understanding of tumor biology, prognostic indicators, and molecular targets against cancer—especially in patients whose treatment options are limited.”

Mohammed Kashani-Sabet, MD, Senior Scientist, Director of CPMC's Cancer Program





“Biomarker-driven therapies offer the potential for truly personalized cancer treatment. We saw dramatic improvements in progression-free survival in patients whose tumors had the target for enzymatic therapy.”

Ari Baron, MD, Chief of the Division of Hematology-Oncology, Medical Director of the Clinical Oncology Research Program

What sets us apart:

- CPMC is a **national leader in developing and conducting clinical trials** for the prevention, diagnosis and treatment of many types of cancer. Enrollment in our oncology clinical trials significantly exceeds the national average.

- We have the **largest mammography center in Northern California**, conducting cutting-edge research on early diagnosis and treatment of breast cancer.


- We lead **groundbreaking cancer research that generates new knowledge about treatment-related disease resistance**—providing novel ways to identify patients potentially responsive to improved treatments and drug combinations including immunotherapies.

- The **Sutter Cancer Research Consortium (SCRC)** is one of the highest enrolling, community oncology sites in the U.S. to National Cancer Institute/NRG Oncology sponsored clinical trials.

- We are **world renowned for investigating and pioneering diagnostic technologies** that help clinicians tailor treatment for the best possible outcomes.

- **Our scientists are among a select group of researchers globally with unique experience** generating cell culture and mouse models of human cancers. This expertise will lead to more personalized therapies, and help oncologists predict how patients will respond to treatment.

Clinical Trial Accrual at CPMC




“Clinical research and coordinated clinical trials at CPMC are moving medicine forward with personalized therapies.”

Kevin Kim, MD, Sutter Pacific Medical Foundation oncologist; Director of Clinical Research at CPMC’s Center for Melanoma Research and Treatment



Research discoveries and advances at CPMCRI:

- Our cancer researchers consistently **publish in high-impact publications** including the world's top medical journal, *The New England Journal of Medicine*.
- Led by **John Chan, MD**, CPMC's gynecologic cancer program is one of the largest in Northern California. Dr. Chan helped pioneer novel molecular and immunotherapeutic approaches.
- Through the **Cancer Avatar Project**, our cancer scientists are working with CPMC oncologists and surgeons to create cell culture and mouse models, or 'avatars', of patients' tumors, which will provide key information about how well a patient's tumor might respond to treatment.
- Survival rates for metastatic melanoma at CPMC's Center for Melanoma Research and Treatment significantly exceed the national average.
- American Society of Clinical Oncology data rank CPMC among the **top five programs in the country** for treating liver cancer.
- We are a **leading center for immunotherapy research**. For example, clinical trials at CPMC were key to the U.S. Food and Drug Administration approval of nivolumab—a breakthrough cancer therapy.



“Sutter Health’s three million patients include a diverse cancer population, allowing us to track outcomes from initial diagnosis through long-term follow-up. This is an exciting project that will accelerate our innovation in personalized medicine research in a way that can ultimately improve patient care.”

Michael Rowbotham, MD, CPMCRI Scientific Director and Cancer Avatar Project Lead

“Instead of static testing—the traditional cancer research approach—using animal models of human tumor growth provides a more dynamic, accurate picture of how tumors grow, metastasize, and respond to cancer drugs.”

Liliana Soroceanu, PhD, MD, a CPMCRI Senior Scientist who leads the basic science component of the Cancer Avatar Project



Sutter Cancer Research Consortium:

The Sutter Cancer Research Consortium (SCRC) enrolls hundreds of patients annually in cancer clinical trials, and has integrated oncology research and studies across CPMC and other Northern California affiliate medical centers.

How SCRC research expertise improves patient care:


- There are **118 registered National Cancer Institute (NCI) investigators** at 20 sites across the Sutter Health network.
- In 2015, **158 patients** were enrolled into NCI-funded clinical trials.
- The SCRC typically has **60-70 clinical trials** open to patient enrollment.
- **Seven** of our oncologists are appointed to sit on NCI national cooperative group Disease Committees, helping lead the design and creation of these studies.
- The SCRC is recognized by the NCI as one of its top clinical trials entities.



The NCI-MATCH trial includes 22 SCRC sites. The groundbreaking study links targeted cancer drugs to gene abnormalities, and will provide patients with faster, streamlined access to more effective therapies.

“The results of our trials are encouraging and show that long-term survival can be achieved in advanced cancers. Our research moves the field toward more individualized approaches to improve survival.”

John Chan, MD, Medical Director of CPMC's Gynecologic Oncology Program and Gynecologic Oncology Lead for the Sutter West Bay Region





“This is the most exciting time in cancer care. Our research allows us to offer patients targeted therapy and immunotherapy based on specific markers found on tumor cells.”

Wei Wang, MD, PhD, medical oncologist,
Medical Director of the Cancer Genetics Program at CPMC

Support cancer research at CPMCRI.
Visit us at www.cpmcri-currents.org

Transformative cancer research for personalized patient care

Clinical trials for cancer prevention and treatment of diverse tumor types

Coordinated cancer research expertise across Sutter Health’s Northern California affiliates

Research that accelerates the development of game-changing cancer drugs

National Cancer Institute-designated cancer center

Internationally renowned cancer scientists and clinicians

“Through clinical research and trials, we’re offering the best possible new treatments to patients across Northern California.”

Stephanie Jeske, MD, CPMC hematologist and medical oncologist,
Co-Director of the Breast Cancer Center of Excellence

